Transparency, Accountability and Cooperation in Medicines Development Francis P. Crawley Commentary 24 August 2012 Pages: 273 - 274
Quality Assurance in Clinical Trials Dagmar ChaseMichael GierendBarbara Schnurr on behalf of the Bundesverband Medizinischer Auftragsinstitute (BVMA) Commentary 24 August 2012 Pages: 275 - 276
Selective Reporting, Publication Bias and Clinical Trial Registry Jesse A. BerlinMary C. Wacholtz Leading Article 24 August 2012 Pages: 277 - 284
Rare Diseases and Essential Medicines Hans V. Hogerzeil Leading Article 24 August 2012 Pages: 285 - 288
Guideline for Auditing Clinical Laboratories Francis P. Crawley Guidelines 24 August 2012 Pages: 289 - 299
Drug Counterfeiting Albert I. WertheimerThomas M. Santella Review Article 24 August 2012 Pages: 301 - 308
Clinical Trials and the Independence of Investigators Roy G. BeranLaetitia A. E. AinleyMaureen E. Beran Concept Article 24 August 2012 Pages: 309 - 316
Prediction of Putative Adverse Drug Reaction-Related Proteins from Primary Sequence by Support Vector Machines Zhi Liang JiLian Yi HanYu Zong Chen Original Research Article 24 August 2012 Pages: 317 - 322
Biotechnology Industry Organization — BIO 2005 Anne Bardsley-Elliot Meeting Report 24 August 2012 Pages: 323 - 332
13th European Cancer Conference — ECCO 13 Andrea Bothwell Meeting Report 24 August 2012 Pages: 333 - 341
Society of Pharmaceutical Medicine Shaun KilminsterMartin W. Lunnon SPM News 24 August 2012 Pages: 365 - 370